15dPMJ2

About Claradele Pharmaceuticals

Claradele Pharmaceuticals is a pre-clinical stage biotechnology company dedicated to developing effective and non-toxic cancer therapeutics. Its core asset is 15dPMJ2, a patented small molecule that uniquely induces cytotoxic ER stress in tumor cells while stimulating an anti-tumor immune response, demonstrating 76% tumor growth reduction in pre-clinical models. The company is initially targeting melanoma in US and European markets, with potential expansion into colon and lung cancers, leveraging its founder's deep academic expertise in oncology research.

About Claradele Pharmaceuticals

Claradele Pharmaceuticals is a pre-clinical stage biotechnology company dedicated to developing effective and non-toxic cancer therapeutics. Its core asset is 15dPMJ2, a patented small molecule that uniquely induces cytotoxic ER stress in tumor cells while stimulating an anti-tumor immune response, demonstrating 76% tumor growth reduction in pre-clinical models. The company is initially targeting melanoma in US and European markets, with potential expansion into colon and lung cancers, leveraging its founder's deep academic expertise in oncology research.

About Claradele Pharmaceuticals

Claradele Pharmaceuticals is a pre-clinical stage biotechnology company dedicated to developing effective and non-toxic cancer therapeutics. Its core asset is 15dPMJ2, a patented small molecule that uniquely induces cytotoxic ER stress in tumor cells while stimulating an anti-tumor immune response, demonstrating 76% tumor growth reduction in pre-clinical models. The company is initially targeting melanoma in US and European markets, with potential expansion into colon and lung cancers, leveraging its founder's deep academic expertise in oncology research.

About Claradele Pharmaceuticals

Claradele Pharmaceuticals is a pre-clinical stage biotechnology company dedicated to developing effective and non-toxic cancer therapeutics. Its core asset is 15dPMJ2, a patented small molecule that uniquely induces cytotoxic ER stress in tumor cells while stimulating an anti-tumor immune response, demonstrating 76% tumor growth reduction in pre-clinical models. The company is initially targeting melanoma in US and European markets, with potential expansion into colon and lung cancers, leveraging its founder's deep academic expertise in oncology research.

About Claradele Pharmaceuticals

Claradele Pharmaceuticals is a pre-clinical stage biotechnology company dedicated to developing effective and non-toxic cancer therapeutics. Its core asset is 15dPMJ2, a patented small molecule that uniquely induces cytotoxic ER stress in tumor cells while stimulating an anti-tumor immune response, demonstrating 76% tumor growth reduction in pre-clinical models. The company is initially targeting melanoma in US and European markets, with potential expansion into colon and lung cancers, leveraging its founder's deep academic expertise in oncology research.

About Claradele Pharmaceuticals

Claradele Pharmaceuticals is a pre-clinical stage biotechnology company dedicated to developing effective and non-toxic cancer therapeutics. Its core asset is 15dPMJ2, a patented small molecule that uniquely induces cytotoxic ER stress in tumor cells while stimulating an anti-tumor immune response, demonstrating 76% tumor growth reduction in pre-clinical models. The company is initially targeting melanoma in US and European markets, with potential expansion into colon and lung cancers, leveraging its founder's deep academic expertise in oncology research.

Therapeutic Areas